Methotrexate
- PDF / 169,401 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 89 Downloads / 126 Views
1 S
Seizure and neurotoxicity: case report In a prospective observational study of 29 patients, who received methotrexate between 1 January 2019 to 15 January 2020, a child [sex not stated; exact age at the time of reaction onset not stated] was described, who developed seizure secondary to neurotoxicity during treatment with methotrexate for acute lymphoblastic leukaemia. The child, who had acute lymphoblastic leukaemia, received high-dose cyclical methotrexate infusion over 24 hours as per BFM protocol-2009 (protocol details not specified) [dosage not stated] with 12 hours of prehydration with sodium bicarbonate. Thirty six hours post-initiation of methotrexate, the child received folinic acid [leucovorin]. Hydration was continued until the last dose of folinic acid. However, the child had an episode of grade 3 seizure secondary to methotrexate neurotoxicity [duration of treatment to reactions onsets and outcomes not stated]. Khera S, et al. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in 803505165 childhood leukemia in resource-limited centers. Pediatric Blood and Cancer 67: No. 7, Jul 2020. Available from: URL: http://doi.org/10.1002/pbc.28387
0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 3 Oct 2020 No. 1824
Data Loading...
